Completed PHASE3 NCT00719862

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-036 in Patients With Seasonal Allergic Rhinitis

Sponsor: Meda Pharmaceuticals

Conditions Seasonal Allergic Rhinitis

Interventions 0.15% azelastine hydrochloride Nasal Spray Placebo nasal spray

Updated 7 times since 2017 Last updated: Jan 27, 2010 Started: Aug 31, 2007 Primary completion: Nov 30, 2007 Completion: Nov 30, 2007

This PHASE3 trial investigates Seasonal Allergic Rhinitis and is currently completed. Meda Pharmaceuticals leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Meda Pharmaceuticals

Data source: Meda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Chester, United States , Dallas, United States , Easton, United States , Edmond, United States , El Paso, United States , Henderson, United States , Huntington Beach, United States , Lakewood, United States , Long Beach, United States and 23 more locations